CN111763257B - 抗gitr抗体及其用途 - Google Patents
抗gitr抗体及其用途 Download PDFInfo
- Publication number
- CN111763257B CN111763257B CN202010900594.7A CN202010900594A CN111763257B CN 111763257 B CN111763257 B CN 111763257B CN 202010900594 A CN202010900594 A CN 202010900594A CN 111763257 B CN111763257 B CN 111763257B
- Authority
- CN
- China
- Prior art keywords
- antibody
- gitr
- antigen
- gly
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010900594.7A CN111763257B (zh) | 2020-09-01 | 2020-09-01 | 抗gitr抗体及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010900594.7A CN111763257B (zh) | 2020-09-01 | 2020-09-01 | 抗gitr抗体及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111763257A CN111763257A (zh) | 2020-10-13 |
CN111763257B true CN111763257B (zh) | 2020-12-15 |
Family
ID=72729218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010900594.7A Active CN111763257B (zh) | 2020-09-01 | 2020-09-01 | 抗gitr抗体及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111763257B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN111234018A (zh) * | 2018-11-29 | 2020-06-05 | 上海开拓者生物医药有限公司 | 全人抗gitr抗体及其制备方法 |
RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
-
2020
- 2020-09-01 CN CN202010900594.7A patent/CN111763257B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111763257A (zh) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7451415B2 (ja) | 腫瘍特異的細胞枯渇のための抗cd25 | |
JP6502590B1 (ja) | 抗Tim−3抗体 | |
CN103221427B (zh) | 抗ox40抗体和使用其的方法 | |
US20170044259A1 (en) | Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof | |
US11873349B1 (en) | Compositions and methods related to IL27 receptor binding | |
KR20200138324A (ko) | Vista 항원 결합 분자 | |
JP2019534282A (ja) | 抗il−33抗体およびその使用 | |
CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
US20210363266A1 (en) | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof | |
JP2021513324A (ja) | 自己免疫疾患およびがんを治療するための抗cxcl13抗体 | |
JP2016512026A (ja) | Pan−ELR+CXCケモカイン抗体 | |
CN111763259B (zh) | 抗cd40抗体及其用途 | |
CN110248960A (zh) | 抗-gitr抗原结合蛋白及其使用方法 | |
EP3456344B1 (en) | Proteins specific for baff and b7rp1 and uses thereof | |
JP7185051B2 (ja) | Cd200rアゴニスト抗体およびそれらの使用 | |
CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
CN110461874B (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
JP2022502417A (ja) | 抗ox40抗体、その抗原結合フラグメント、および医薬用途 | |
CN111808196B (zh) | 抗pd-1抗体及其用途 | |
CN111763257B (zh) | 抗gitr抗体及其用途 | |
WO2022228445A1 (en) | Single domain pd-l1 antibodies | |
AU2022285741A1 (en) | Anti-ccr8 antibodies and uses thereof | |
CN111763258B (zh) | 抗ox40抗体及其用途 | |
JP2023531042A (ja) | 4-1bb結合タンパク質及びその用途 | |
EP4159859A1 (en) | Anti-human nr1 antibody derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 102609 No.12, Baoshen South Street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: Baccetus (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: 102629 No.12, Baoshen South Street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee before: BEIJING BIOCYTOGEN Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211118 Address after: 215128 unit E600, 5 / F, Lecheng Plaza, phase II, biomedical industrial park, 218 Sangtian street, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Patentee after: DOMA Pharmaceutical Technology (Suzhou) Co.,Ltd. Address before: 102609 No.12, Baoshen South Street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee before: Baccetus (Beijing) Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |